Results of a pivotal phase III study of Supernus Pharmaceuticals’ SPN-812 (viloxazine extended-release capsules) were published in the journal Clinical Therapeutics.

Yumanity Therapeutics and Merck signed a strategic research and license deal for two Yumanity programs. The two preclinical programs are for amyotrophic lateral sclerosis (ALS) and frontotemporal lobar dementia (FTLD).

The U.S. Food and Drug Administration granted clearance for Akili’s EndeavorRx as a prescription treatment for children with attention deficit hyperactivity disorder (ADHD).

David Lickrish – president, founder and chief executive officer of Highland Therapeutics and Ironshore Therapeutics – spoke with BioSpace about the companies’ Jornay PM (methylphenidate HCL Extended-Release CLL Capsules) and how the new drug fits into the overall ADHD therapeutic market.

Renaissance genius Leonardo da Vinci’s litany of exquisite but unfinished work shows he probably had an attention disorder common to modern society.

Researchers from Amen Clinics, Google, Johns Hopkins University, UCLA, and UC San Francisco studied 62,454 brain scans of more than 30,000 people to study brain aging.

Scientists in Brazil have uncovered a new brain disorder associated with Zika infections in adults: an autoimmune syndrome called acute disseminated encephalomyelitis, or ADEM, that attacks the brain and spinal cord.   Zika has already been linked with the autoimmune disorder Guillain-Barre syndrome, which attacks peripheral nerves outside the brain and spinal cord, causing temporary […]

One in three people born in Britain in 2015 will develop dementia, according to an analysis commissioned by the charity campaign group Alzheimer’s Research UK. The study, conducted by the Office of Health Economics, shows “a looming national health crisis as the UK population ages”, the charity said, and underlines the need for global efforts […]

EVANSTON, Ill., Sept. 16, 2015 /PRNewswire/ — Aptinyx Inc., a biopharmaceutical company advancing modulators of the N-methyl-D-aspartate (NMDA) receptor for the treatment of challenging disorders of the brain and nervous system, has launched with the discovery platform and preclinical pipeline spun out of Naurex upon the close of its acquisition by Allergan in August 2015. “As […]